• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19

tetano

Editor, Senior Moderator
Front Immunol


. 2022 Nov 3;13:1027122.
doi: 10.3389/fimmu.2022.1027122. eCollection 2022.
Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19


Martijn Zoodsma[SUP] 1 2 [/SUP], Aline H de Nooijer[SUP] 3 [/SUP], Inge Grondman[SUP] 3 [/SUP], Manoj Kumar Gupta[SUP] 1 2 [/SUP], Agnes Bonifacius[SUP] 4 [/SUP], Valerie A C M Koeken[SUP] 1 2 3 [/SUP], Emma Kooistra[SUP] 3 [/SUP], Gizem Kilic[SUP] 3 [/SUP], Ozlem Bulut[SUP] 3 [/SUP], Nina Gödecke[SUP] 4 [/SUP], Nico Janssen[SUP] 3 [/SUP], Matthijs Kox[SUP] 5 [/SUP], Jorge Domínguez-Andrés[SUP] 3 [/SUP], Adriaan J van Gammeren[SUP] 6 [/SUP], Anton A M Ermens[SUP] 6 [/SUP], Andre J A M van der Ven[SUP] 3 [/SUP], Peter Pickkers[SUP] 5 [/SUP], Rainer Blasczyk[SUP] 4 [/SUP], Georg M N Behrens[SUP] 1 7 8 [/SUP], Frank L van de Veerdonk[SUP] 3 [/SUP], Leo A B Joosten[SUP] 3 9 [/SUP], Cheng-Jian Xu[SUP] 1 2 3 [/SUP], Britta Eiz-Vesper[SUP] 4 [/SUP], Mihai G Netea[SUP] 3 10 [/SUP], Yang Li[SUP] 1 2 3 [/SUP]



Affiliations

Abstract

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic is caused by the highly infectious Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). There is an urgent need for biomarkers that will help in better stratification of patients and contribute to personalized treatments. We performed targeted proteomics using the Olink platform and systematically investigated protein concentrations in 350 hospitalized COVID-19 patients, 186 post-COVID-19 individuals, and 61 healthy individuals from 3 independent cohorts. Results revealed a signature of acute SARS-CoV-2 infection, which is represented by inflammatory biomarkers, chemokines and complement-related factors. Furthermore, the circulating proteome is still significantly affected in post-COVID-19 samples several weeks after infection. Post-COVID-19 individuals are characterized by upregulation of mediators of the tumor necrosis (TNF)-α signaling pathways and proteins related to transforming growth factor (TGF)-ß. In addition, the circulating proteome is able to differentiate between patients with different COVID-19 disease severities, and is associated with the time after infection. These results provide important insights into changes induced by SARS-CoV-2 infection at the proteomic level by integrating several cohorts to obtain a large disease spectrum, including variation in disease severity and time after infection. These findings could guide the development of host-directed therapy in COVID-19.

Keywords: SARS-CoV-2; biomarker; inflammation; post-COVID-19; targeted proteomics.
 
Back
Top Bottom